Kinarus Therapeutics engages Great Health Companion group to explore partnerships in China

  • Kinerus at explore partnerships in China finance Phase 2 clinical trials of KIN001 and explore other business opportunities
  • Mmultiple opportunities for KIN001 in high unmet need indications are good-matchD to Chinese market

Basel, Switzerland, 16 November 2022. Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company developing novel treatments to treat viral, respiratory and ophthalmic diseases, today announced that it has committed Great Health Companion Group Ltd (GHCG), a subsidiary of Hakim Single Groupa global conglomerate of China, to explore partnership options to initiate phase 2 testing of KIN001 to treat wet age-related macular degeneration (AMD) and idiopathic pulmonary fibrosis (IPF). Additionally, Kinarus and GHCG will explore other business opportunities which may include licensing or strategic partnerships.

Doctor Alexander BauschCEO of Kinarus Therapeutics Holding SAcommented : “China has the largest population in the world and the second largest economy. China’s economic growth has increased its ability to invest heavily in innovation technologies, infrastructure and health care for its people. Due to their large aging population, the demands of health care demand that public and private organizations, both national and international, work together to achieve mutual success. Additionally, Chinese partners have historically shown strong interest in Phase 2 clinical assets with proven potential to address unmet medical needs in China. KIN001 meets these criteria and for this reason we are pleased to engage GHCG to represent us in China.

“Kinarus is ready to initiate Phase 2 trials in wAMD and IPF, and is currently conducting a Phase 2 trial of KIN001 in outpatient Covid-19 patients aimed at reducing symptom severity and duration. We look forward to working closely with GHCG as we seek to accelerate the clinical development of KIN001 and maximize the value and opportunities it represents. »

Kinerus Clinical programs:

  • KIN001-AMD Phase 2 trial – KIN001 is being developed as an add-on oral therapy to current anti-VEGF drugs with the aim of extending the treatment interval between ocular injections. Kinarus has received regulatory approval to conduct a Phase 2 clinical study in Swiss and Germany.
  • KIN001REITs Phase 2 trial – IPF is a devastating disease with high morbidity and mortality and significant unmet need. KIN001 targets multiple mechanisms underlying disease progression, reducing irreversible fibrosis and loss of respiratory capacity. Protocol development is complete and regulatory submissions are expected once the AMD trial is launched.
  • KINFAST Phase 2 trial in Covid-19 – KIN001 targets several of the underlying mechanisms of acute and long Covid. Recent research has shown that the SARS-CoV-2 virus hijacks the p38 MAPK pathway for its replication in infected cells. Kinarus, as well as collaborators from Institute of Virology, Friedrich-Alexander-University, Germany, found that KIN001 is active against SARS-CoV-2 and its variants of concern. KIN001 also has anti-inflammatory and anti-fibrotic activity. The KINFAST Phase 2 trial is currently actively recruiting patients in Swiss and Germany. We expect interim results in 2023.

KIN001 is a patented combination of two active pharmaceutical ingredients (API): pamapimod and pioglitazone. Pamapimod is a clinical-stage, highly selective small molecule inhibitor of the p38 MAP kinase signaling pathway. Kinarus has obtained an exclusive worldwide license from Roche for the development of pamapimod in all therapeutic indications. p38 MAPK inhibitors have been widely considered to have blockbuster potential, with several compounds being evaluated in mid-stage clinical trials. Most efforts were abandoned after it was found that the initial therapeutic benefit of p38 MAPK inhibition diminished over time due to compensatory mechanisms that blocked its beneficial effects.

Kinarus discovered a potential way to overcome this limitation. Kinarus found that the combination of pamapimod with pioglitazone, a safe and well-tolerated marketed drug for the treatment of type 2 diabetes, leads to synergistic efficacy and increased duration of action in preclinical models of wAMD, IPF and other autoimmune/inflammatory indications. The KIN001 drug combination thus revives the important therapeutic potential of p38 MAPK inhibition. KIN001 enjoys extensive patent protection in the US, EU, Chinaand other countries until at least 2037, with intellectual property fully owned by Kinarus.

Kinerus Therapeutics Holding SA (www.kinarus.com) was founded in 2017 by experienced pharmaceutical executives in Basel, Switzerland. The Kinarus team uses its drug development knowledge and skills to in-license and develop mid-stage clinical assets in which they have identified an increased likelihood of clinical and regulatory success and a rapid path to market. Kinarus owns the exclusive worldwide license to pamapimod covering all indications.

Contacts

Kinerus Therapeutic Holding SA
Hochbergerstraße 60C
4057 Basel, Switzerland
+41 61 633 29 71
[email protected]
Investors & MediaChris MaggosBioConfidant Sàrl
+41 79 367 6254
[email protected]

Legal disclaimer

THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO SELL OR AN INVITATION TO SUBMIT A PROPOSAL TO ACQUIRE SECURITIES OF KINARUS THERAPEUTICS HOLDING AG. THIS PRESS RELEASE IS NOT INTENDED FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN ANY JURISDICTION WHERE IT IS ILLEGAL FOR DISTRIBUTION.

main logo

Source: Kinarus Therapeutic Holding SA

2022 GlobeNewswire, Inc., source Press Releases